Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.64 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149470 | 1.00 | GPR119 (0.64) | GPR119GPR183KCNH2LMNAMAPT | |
| SCHEMBL3262057 | 0.87 | GPR119 (0.60) | GPR119GPR183KCNH2 | |
| SCHEMBL3262064 | 0.87 | GPR119 (0.60) | GPR119GPR183KCNH2 | |
| SCHEMBL388674 | 0.85 | GPR119 (0.73) | GPR119GPR183KCNH2LMNAMAPT | |
| SCHEMBL384918 | 0.85 | GPR119 (0.73) | GPR119GPR183KCNH2LMNAMAPT | |
| SCHEMBL470543 | 0.85 | GPR119 (0.73) | GPR119GPR183KCNH2LMNAMAPT | |
| SCHEMBL148263 | 0.84 | GPR119 (0.44) | GPR119LMNAMAPT | |
| SCHEMBL148262 | 0.84 | GPR119 (0.44) | GPR119LMNAMAPT | |
| SCHEMBL461917 | 0.82 | GPR119 (0.61) | GPR119GPR183KCNH2LMNAMAPT | |
| SCHEMBL461916 | 0.82 | GPR119 (0.61) | GPR119GPR183KCNH2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| EP-2383270-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| EP-2114931-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011128394-A1 | 3-SUBSTITUTED 5-(PYRROLIDINE-1-CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2011-10-20 | — | — | WO | disclosed |
| EP-2377864-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377863-A1 | Piperidine GPCR agonists | Prosidion Limited (GB) | 2011-10-19 | — | — | EP | disclosed |
| EP-2114933-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| EP-2114935-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-07-20 | — | — | EP | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100048632-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| WO-2010004345-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004347-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| EP-2114935-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114931-A1 | PIPERIDINE GPCR AGONISTS | Prosidion Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008081207-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081205-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885GPR183 45/4885KCNH2 1128/4885 |
| US-20100048632-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885GPR183 45/4885KCNH2 1128/4885 |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885GPR183 48/4885KCNH2 2010/4885 |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885GPR183 45/4885KCNH2 1128/4885 |
| US-20110212939-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885GPR183 29/4885KCNH2 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.